In the present thesis, different formulations of tacrolimus for topical-ophthalmic administration have been proposed, supported by extensive preclinical studies in order to achieve a consistent basis for the treatment of ocular inflammatory diseases. On the other hand, a pharmacokinetic and distribution study of an anti-TNFα monoclonal antibody (adalimumab) injected intravitreally was also carried out, allowing to know its behavior in the eye and thus develop new administration systems.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados